Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Test Cost & Procedure

The following objectives are achieved with this test:

• Detection of inflammatory imaging illnesses of the mouth.
• Autoimmune myelin oligodendrocyte glycoprotein detection.
• Neuromyelitis Optica discovered
• Discovery of ADEM

Myelin oligodendrocyte glycoprotein: what is it?

There is now recognition of myelin oligodendrocyte glycoprotein (MOG)-IgG as a sensitive and specific diagnostic antibody biomarker of demyelinating inflammatory diseases (IDDs).

• There is yet no MS-specific biomarker (multiple sclerosis). Patients who test positive for MOG-IgG frequently have MS misdiagnosed. The presence of MOG-IgG suggests a demyelinating inflammatory condition different from MS. Making the proper diagnosis is crucial because MS medications may worsen MOG-IgG-associated IDDs.
• Acute disseminated encephalomyelitis (ADEM), transverse myelitis, and optic neuritis are examples of NMOSD-like illnesses where seropositivity for MOG-IgG predicts relapse and justifies consideration of continuous immunosuppression.
• When central nervous system (CNS) demyelination has severely relapsed, seropositivity for MOG-IgG justifies intensive therapy using intravenous methylprednisolone or plasmapheresis.

What is Optica Neuromyelitis?

It is an autoimmune disease that is inflammatory and causes demyelination of the central nervous system and the deterioration of at least one optical nerve's insulating sheath (Neuritis Neopticstici) and the spinal cord at the same time or a few months later (Myelitis). 60% to 90% of patients have detectable anti-aquaporin-4 antibodies. However, antibodies against MOG are generated in 7.4% of patients. MOG antibodies are present in 21.1% of sera from patients who are not aquaporin-4-4 negative.

Results interpretation:

On the myelin sheath, myelin oligodendrocyte glycoprotein is expressed. Multiple sclerosis may be associated with a shallow frequency of elevated MOG antibodies. When neuromyelitis optica/neuromyelitis optica spectrum disorders (NMO/NMOSD) are suspected in anti-aquaporin 4-negative patients, they should still be evaluated.

• When compared to CSF, the serum is more sensitive to the detection of MOG antibodies. Anti-MOG antibodies may occasionally be seen in CSF in patients with high blood levels of these antibodies, indicating that the blood-brain barrier has allowed the antibodies from the blood to cross. Uncertainty surrounds the importance of anti-MOG antibodies in CSF.
• With only five underlying cancer instances recorded, antibodies against MOG are classified as lower-risk. According to Updated Diagnostic, a favourable outcome results in a PNS score of 0.